CTRI/2009/091/000216已完成3 期
A 26-Week Extension to a 26-Week Treatment, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease
ovartis Healthcare Pvt Ltd0 个研究点目标入组 418 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 418
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients eligible to participate in the study extension, by definition, will have met the inclusion and exclusion criteria for the core 26 weeks and not met the withdrawal criteria for the core study B2335S at Visit 14 (the last visit of the core study B2335S and the first visit of the extension study B2335SE)
- •In addition the following inclusion/exclusion criteria specified below must be met.
- •Patients must complete Stage 2 of the core study B2335S.
- •Written informed consent to participate in the extension must be obtained.
- •Patients must be able to comply with all study requirements.
排除标准
- •*Patients who were randomized to open-label tiotropium in Study B2335S.
- •* Patients who participated in Stage 1 of the core study (B2335S).
- •*Patients discontinued irrespective of the reason from Stage 2 of the core study.
- •*Patients who fail to comply with the core protocol requirements and procedures.
- •*Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.
- •*Patients who in the Investigator's opinion should not-participate in the extension study.
研究者
相似试验
进行中（未招募）
不适用
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 µg o.d.) in patients with chronic obstructive pulmonary disease.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-000663-42-DEovartis Pharma Services AG500
进行中（未招募）
不适用
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 μg o.d.) in patients with chronic obstructive pulmonary disease. - NDBPCOMedDRA version: 9.1Level: LLTClassification code 10009026Term: Chronic obstructive airways diseaseEUCTR2008-000663-42-ITOVARTIS FARMA1,300
进行中（未招募）
不适用
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 µg o.d.) in patients with chronic obstructive pulmonary disease.EUCTR2008-000663-42-SEovartis Pharma Services AG417
进行中（未招募）
不适用
A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary DiseaseEUCTR2010-023621-37-EEovartis Pharma Services AG522
进行中（未招募）
不适用
A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary DiseaseEUCTR2010-023621-37-HUovartis Pharma Services AG522